Scarica l'app Stockscreener
3.80
5.00%
-0.20
Dopo l'orario di chiusura:
3.76
-0.04
-1.05%
Precedente Chiudi:
$4.00
Aprire:
$4
Volume 24 ore:
397.09K
Relative Volume:
2.38
Capitalizzazione di mercato:
$20.57M
Reddito:
-
Utile/perdita netta:
$-21.21M
Rapporto P/E:
-0.1166
EPS:
-32.6
Flusso di cassa netto:
$-16.86M
1 W Prestazione:
-12.64%
1M Prestazione:
-3.31%
6M Prestazione:
-9.09%
1 anno Prestazione:
-13.64%
Intervallo 1D:
$3.75
$4.155
Intervallo di 1 settimana:
$3.73
$4.40
Portata 52W:
$3.02
$6.01
Cingulate Inc Stock (CING) Company Profile
Nome
Cingulate Inc
Settore
Industria
Telefono
(913) 942-2300
Indirizzo
1901 W. 47TH PLACE, KANSAS CITY
Confronta CING con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
3.80 | 23.27M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | ROTH MKM | Buy |
| 2023-12-22 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Borsa (CING) Ultime notizie
Will Cingulate Inc. stock remain a Wall Street favoriteVolume Spike & Daily Momentum Trading Reports - newser.com
How Cingulate Inc. stock compares to industry benchmarksTrade Risk Assessment & High Conviction Buy Zone Alerts - newser.com
Roth Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Is Cingulate Inc. stock bottoming outJuly 2025 Intraday Action & Free Fast Gain Swing Trade Alerts - newser.com
What institutional flow reveals about Cingulate Inc.Weekly Trade Review & Expert Verified Stock Movement Alerts - newser.com
Strategic Advancements and Partnerships Propel Cingulate Inc. Towards Market Success - TipRanks
Backtesting results for Cingulate Inc. Equity Warrant trading strategiesMarket Growth Summary & Daily Risk Controlled Trade Plans - newser.com
How supply chain issues affect Cingulate Inc. stock2025 Investor Takeaways & Expert Verified Movement Alerts - newser.com
Why Cingulate Inc. stock could be next big winnerJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
Does Cingulate Inc. fit your quant trading modelMarket Rally & Smart Investment Allocation Tips - newser.com
Can Cingulate Inc. stock deliver consistent earnings growth2025 Stock Rankings & Daily Chart Pattern Signals - newser.com
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review Retail Bets On Buyout Potential - Menafn.com
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential - Asianet Newsable
Will Cingulate Inc. continue its uptrendJuly 2025 Earnings & Long-Term Safe Return Strategies - newser.com
FDA accepts Cingulate’s ADHD drug application, sets May 2026 target date - Investing.com Canada
What’s next for Cingulate Inc. stock priceJuly 2025 Opening Moves & Entry and Exit Point Strategies - newser.com
Cingulate receives target date for when it could receive FDA approval - The Business Journals
Cingulate Inc’s NDA for CTx-1301 Accepted by FDA - TipRanks
Cingulate announces FDA accepted for review the NDA for CTx-1301 - TipRanks
Cingulate Inc FDA Accepts NDA for CTx-1301 for ADHD - TradingView
FDA Accepts Cingulate’s New Drug Application for CTx-1301 - GlobeNewswire
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date - Yahoo Finance
Will Cingulate Inc. bounce back from current support2025 Retail Activity & Verified Entry Point Signals - newser.com
Can Cingulate Inc. Equity Warrant stock deliver consistent earnings growth2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
How Cingulate Inc. Equity Warrant stock trades before earningsWatch List & Daily Market Momentum Tracking - newser.com
Is it too late to sell Cingulate Inc.Quarterly Growth Report & AI Forecast for Swing Trade Picks - newser.com
Is Cingulate Inc a good long term investmentREITs Market Trends & Rapid Portfolio Strategies - earlytimes.in
Cingulate Inc. (NASDAQ:CING) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Is Cingulate Inc. stock entering bullish territoryCEO Change & Smart Money Movement Alerts - newser.com
Analyzing drawdowns of Cingulate Inc. Equity Warrant with statistical tools2025 Year in Review & Stock Timing and Entry Methods - newser.com
Market reaction to Cingulate Inc.’s recent newsDividend Hike & Consistent Income Trade Ideas - newser.com
Is Cingulate Inc. a candidate for recovery playInsider Selling & Weekly Chart Analysis and Guides - newser.com
Cingulate Inc. stock retracement – recovery analysisTrade Volume Summary & Risk Controlled Stock Pick Alerts - newser.com
What does recent volatility data suggest for Cingulate Inc.Trade Analysis Report & Verified Swing Trading Watchlist - newser.com
Using flow based indicators on Cingulate Inc.July 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com
Will Cingulate Inc. stock gain from government policiesJuly 2025 PostEarnings & Real-Time Chart Breakout Alerts - newser.com
Cingulate Inc Azioni (CING) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):